Androgen deprivation therapy plus abiraterone or docetaxel as neoadjuvant therapy for very-high-risk prostate cancer: a pooled analysis of two phase II trials

Conclusion: Compared with ADT alone, neoadjuvant therapy with ADT plus docetaxel or abiraterone could achieve better pathological outcomes (pCR or MRD) for very-high-risk localized prostate cancer. The ADT plus abiraterone group showed longer bPFS than ADT alone. The combination regimens were tolerable.PMID:37435500 | PMC:PMC10331422 | DOI:10.3389/fphar.2023.1217303

Source: Cancer Control - July 12, 2023 Category: Cancer & Oncology Authors: Junlong Zhuang Yuwen Wang Shun Zhang Yao Fu Haifeng Huang Xiaoyu Lyu Shiwei Zhang Giancarlo Marra Linfeng Xu Xuefeng Qiu Hongqian Guo Source Type: research